Novavax Inc. (NVAX)
Loading...
Symbols:
NVAX Forum Topics
- All Comments on NVAX
- General Discussion on NVAX
- Biotech Day in Review: Hopeful Results from HIV Conference [view article]
loading ...Recent NVAX Articles
- Biotech Day In Review: Roche Picks Up Antibody Firm For $56.5 Million
- Biotech Day in Review: Hopeful Results from HIV Conference
- Biosante: Tiny Biotech Could Skyrocket with Estrogen Replacement Gel
- Novavax Advances Avian Flu Vaccine Despite Government Snub
- Biotech Stocks Day-In-Review: Coley Drops After Ending Hepatitis C Program
- Novavax Should Jump On Avian Flu Results
- Biotech Stocks Day-in-Review: BioCryst Begins Pivotal Trial of Fodosine
- Smallcap Novavax Has Turned a Corner
-
Earnings Schedule and Estimates for Monday, August 14, 2006
on Aug 14, 2006| by
- Novavax Stuck in Downtrend
- Full List of Articles »
Trading Center
Hedge Fund Jobs
Job Seekers: Search jobs by category, get job alerts by email or live feed, apply online See full list of jobs »
Employers: See all recruitment options, get applications online or by email Post a job »
General Discussion on NVAX
Current Recommendation: MARKET OUTPERFORMSep 14, 2008 (Nelson's Broker Summaries via COMTEX) --
Company: NOVAVAX INC
Report Headline: "NVAX: ANNOUNCES NEW DISCOVERY PROGRAM FOR VARICELLA ZOSTER VIRUS (VZV) VACCINE"
Report Date: September 12, 2007
Current Recommendation: MARKET OUTPERFORM
Research Firm: YZJ
Analyst: NAVDEEP S JAIKARIA
Industry: HEALTH/BIOTECH
Estimates reported in USD Reply
Biotech Day in Review: Hopeful Results from HIV Conference [view article]
NVAX keeps working on it!! ReplyGeneral Discussion on NVAX
Test results to be released Monday, August 25. Expectations are for +ive results. ReplyGeneral Discussion on NVAX
Novavax to Present Phase I/IIa Trial Data Results in an Investor Conference Call on August 26, 2008Thursday August 21, 8:00 am ET
ROCKVILLE, Md., Aug. 21 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX - News) today announced that the Company will hold an investor conference call to discuss results from the Phase I/IIa human clinical trial of Novavax's H5N1 pandemic influenza VLP vaccine candidate at 11:00 a.m. Eastern Time on August 26, 2008. The call will be hosted by Novavax President and Chief Executive Officer Dr. Rahul Singhvi and other members of senior management, including Chief Medical Officer, Dr. Penny Heaton. A question and answer session will follow the presentation of the data. The dial-in number for the conference call is USA and Canada (866) 244 4515, International: (703) 639 1168. A live audio webcast of the conference call will be available at novavax.com. Please connect to this website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. A replay of the webcast will be available for 90 days after the webcast and a replay of the conference call will also be available by telephone beginning 1pm EDT, August 26, 2008 through midnight September 2, 2008. To access the replay, dial (703) 925 2533 and enter pass code 1272626.
About Novavax, Inc.
Novavax, Inc. is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. Additional information about Novavax is available at novavax.com and in the Company's various filings with the Securities and Exchange Commission.
Reply
General Discussion on NVAX
Needs more clinical test data before legit recommendations can be made. ReplyBiotech Day in Review: Hopeful Results from HIV Conference [view article]
is a fastest service. ReplyEditors
General Discussion on NVAX
Is this a buy or a sell? Reply